Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT: Olmesartan in diabetic nephropathy
NCT00141453Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2003
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in diabetic nephropathy (DN) comparing Olmesartan with Placebo (2 arms). Primary endpoint: Renal Composite Outcomes at 5 years. Started Apr 2003; status: completed.
02
Drugs
olmesartan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00141453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141453.